These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22668963)
1. Treatment of carcinoma of the anal canal at Groote Schuur Hospital. Robertson B; Shepherd L; Abratt RP; Hunter A; Goldberg P S Afr Med J; 2012 May; 102(6):559-61. PubMed ID: 22668963 [TBL] [Abstract][Full Text] [Related]
2. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146 [TBL] [Abstract][Full Text] [Related]
3. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal. Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820 [TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. White EC; Goldman K; Aleshin A; Lien WW; Rao AR Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494 [TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173 [TBL] [Abstract][Full Text] [Related]
6. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D; Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136 [TBL] [Abstract][Full Text] [Related]
7. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775 [TBL] [Abstract][Full Text] [Related]
8. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Voong KR; Rashid A; Crane CH; Minsky BD; Krishnan S; Yao JC; Wolff RA; Skibber JM; Feig BW; Chang GJ; Das P Am J Clin Oncol; 2017 Dec; 40(6):555-560. PubMed ID: 26237193 [TBL] [Abstract][Full Text] [Related]
9. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724 [TBL] [Abstract][Full Text] [Related]
10. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585 [TBL] [Abstract][Full Text] [Related]
11. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058 [TBL] [Abstract][Full Text] [Related]
12. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071 [TBL] [Abstract][Full Text] [Related]
13. Review of anal cancer patients at the Ottawa hospital. Abunassar M; Reinders J; Jonker DJ; Asmis T Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438 [TBL] [Abstract][Full Text] [Related]
14. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Klas JV; Rothenberger DA; Wong WD; Madoff RD Cancer; 1999 Apr; 85(8):1686-93. PubMed ID: 10223561 [TBL] [Abstract][Full Text] [Related]
15. Twenty-five-year experience with radical chemoradiation for anal cancer. Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078 [TBL] [Abstract][Full Text] [Related]
16. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma. El-Hadaad HA; Wahba HA; Roshdy S J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165 [TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Ott OJ; Schmidt M; Semrau S; Strnad V; Matzel KE; Schneider I; Raptis D; Uter W; Grützmann R; Fietkau R Strahlenther Onkol; 2019 Jul; 195(7):607-614. PubMed ID: 30390114 [TBL] [Abstract][Full Text] [Related]
19. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327 [TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]